Given the previously described role of DNA hypermethylation in MSH2 promoter silencing due to EPCAM unterminated transcription, we utilized targeted methylation sequencing to map the DNA methylation status of the MSH2 promoter in blood, fibroblast, colon-derived primary organoids, GI polyp and adenocarcinoma tissue. This evidence concerns the gene MSH2 and adenocarcinoma.